Skip to main navigation Skip to search Skip to main content

TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

  • M. Jasek
  • , L. P. Gondek
  • , N. Bejanyan
  • , R. Tiu
  • , J. Huh
  • , K. S. Theil
  • , C. O'Keefe
  • , M. A. McDevitt
  • , J. P. MacIejewski

Research output: Contribution to journalLetterpeer-review

76 Scopus citations
Original languageEnglish
Pages (from-to)216-219
Number of pages4
JournalLeukemia
Volume24
Issue number1
DOIs
StatePublished - Jan 2010

Bibliographical note

Funding Information:
This work was supported in part by RO1HL-082983, U54 RR019391 K24 HL-077522 and by Grant from AA&MDS International Foundation and Robert Duggan Charitable Fund (JPM).

Cite this